Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Glaucoma”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources
PubMed1990

Focal ischaemic normal pressure glaucoma versus high pressure glaucoma.

In a total group of 130 patients with Normal Pressure Glaucoma (NPG) twenty-six were classified as Focal Ischaemic NPG (FINPG). This subgroup has a typical defect at the disc with a comparable visual field defect in the corresponding half of the visual field. Visual field defects are more often seen in the upper than the lower half of the visual field. The defects in the upper half are on the average larger (stage 1.6) than those in the lower half (stage 0.9). Abnormalities of the chamber angle were observed in 12% of these patients, the same percentage as in the normal population. Hypertension and/or cardiovascular disorders were found significantly more frequently in FINPG patients (65.4%) than in a control group of High Pressure Glaucoma (HPG) patients (22.2%). Of the local vascular risk factors, papillary haemorrhages (46%) and choroidal sclerosis (30%) were seen significantly more frequently in FINPG than in HPG (11% and 0% respectively). The total amount of peripapillary atrophy (PPA) in FINPG and HPG is the same, but the distribution is clearly different: in FINPG there is more PPA on the side of the papillary defect. Wide veins were observed in a high percentage of cases in both groups. FINPGs were found to be more frequently progressive (38.5%) than had been thought at first. Recognition of subgroups in NPG, and of risk factors, has already made it possible to make a better prognosis in some types of NPG.

Adult↗
PubMed1989

Glaucoma drainage tubes--their role in glaucoma management.

The results are presented from 100 eyes operated upon with either the ACTSEB procedure or a one piece tube and plate that have been followed for greater than 12 months. An intraocular pressure control was considered 'successful' if less than 21 mm Hg. The success varied according to the diagnostic category and its type of operation. One third of the total group did not require antiglaucomatous medications. Higher success rates were found in the one piece than the ACTSEB procedure. Overall success rates at 18 months per diagnostic group ranged between 41% in the neovascular glaucomas to 83% in the chronic simple glaucomas.

Adolescent↗
PubMed1986

Comparison of visual field defects in normal-tension glaucoma and high-tension glaucoma.

In a prospective comparison of visual defects in 23 patients with normal-tension glaucoma and 23 with high-tension glaucoma, the groups were matched for equal involvement of the optic disk. F profiles on the Octopus 201 Perimeter were used to quantify thresholds at 1-degree intervals from fixation to define eccentricity, depth, and slope of the scotoma. The mean eccentricity of scotomas in the normal-tension group was 4.86 degrees from fixation; in the high-tension group it was 2.96 degrees. These differences were statistically significant (P less than .01). No statistically significant differences were found between the slopes of the scotomas or depths of the scotomas in the two groups.

Adult↗
PubMed1991

The Glaucoma Laser Trial (GLT): 3. Design and methods. Glaucoma Laser Trial Research Group.

The Glaucoma Laser Trial (GLT) was an investigator-initiated, grant-supported, multicenter, randomized, controlled clinical trial designed to investigate the efficacy and safety of argon laser trabeculoplasty (ALT) as an alternative to medical treatment for newly diagnosed primary open-angle glaucoma (POAG). One eye of each patient was randomly assigned to ALT followed by medical treatment if needed to control intraocular pressure (IOP). The patient's other eye was assigned to medical treatment. Medical treatment for either eye was prescribed according to a stepped sequence. Patients were followed for a minimum of 2 years. Monitoring for control of IOP and for adherence to the protocol continued throughout the followup period. This article describes the design and methods of the trial and provides a discussion of the underlying rationale for key design decisions.

Double-Blind Method↗
PubMed2002

The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma.

PURPOSE: To examine the relationships between baseline risk factors and sustained decrease of visual field (SDVF) and sustained decrease of visual acuity (SDVA). DESIGN: Cohort study of participants in the Advanced Glaucoma Intervention Study (AGIS). METHODS: This multicenter study enrolled patients between 1988 and 1992 and followed them until 2001; 789 eyes of 591 patients with advanced glaucoma were randomly assigned to one of two surgical sequences, argon laser trabeculoplasty (ALT)-trabeculectomy-trabeculectomy (ATT) or trabeculectomy-ALT-trabeculectomy (TAT). This report is based on data from 747 eyes. Eyes were offered the next intervention in the sequence upon failure of the previous intervention. Failure was based on recurrent intraocular pressure elevation, visual field defect, and disk rim criteria. Study visits occurred every 6 months; potential follow-up ranged from 8 to 13 years. For each intervention sequence, Cox multiple regression analyses were used to examine the baseline characteristics for association with two vision outcomes: SDVF and SDVA. The magnitude of the association is measured by the hazard ratio (HR), where HR for binary variables is the relative change in the hazard (or risk) of the outcome in eyes with the factor divided by the hazard in eyes without the factor, and HR for continuous variables is the relative change in the hazard (or risk) of the outcome in eyes with a unit increase in the factor. RESULTS: Characteristics associated with increased SDVF risk in the ATT sequence are: less baseline visual field defect (hazard ratio [HR] = 0.86, P <.001, 95% CI = 0.82-0.90), male gender (HR = 2.23, P <.001, 1.54-3.23), and worse baseline visual acuity (HR = 0.96, P =.001, 0.94-0.98); in the TAT sequence: less baseline visual field defect (HR = 0.93, P =.001, 0.89-0.97) and diabetes (HR = 1.87, P =.007, 1.18-2.97). Characteristics associated with increased SDVA risk in both treatment sequences are better baseline acuity (ATT: HR = 1.05, P <.001, 1.02-1.09; TAT: HR = 1.06, P <.001, 1.03-1.08), older age (ATT: HR = 1.05, P =.001, 1.02-1.08; TAT: HR = 1.04, P =.002, 1.01-1.06), and less formal education (ATT: HR = 1.92, P =.001, 1.29-2.88; TAT: HR = 1.77, P =.002, 1.22-2.54). CONCLUSIONS: For SDVF, risk factors were better baseline visual field in both treatment sequences, male gender, and worse baseline visual acuity in the ATT sequence, and diabetes in the TAT sequence. For SDVA, risk factors in both treatment sequences were better baseline visual acuity, older age, and less formal education.

Aged↗
PubMed1995

The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group.

PURPOSE: To determine the differences in visual fields during 42 months (3 1/2 years) of follow-up between eyes treated with argon laser trabeculoplasty first and eyes treated with topical medication first in patients with newly diagnosed primary open-angle glaucoma. METHODS: Visual field examinations were obtained at enrollment, three and six months, and at six-month intervals thereafter during follow-up of 271 patients enrolled in the Glaucoma Laser Trial. Numeric analyses of the examination results, including global indices and patterns of localized changes, as well as masked subjective clinical impression, were used to compare the two treatment groups. RESULTS: The mean threshold for eyes treated with laser trabeculoplasty first was 0.3 dB better than that for eyes treated with topical medication first averaged over follow-up (95% confidence interval, [-0.1, 0.7]; P = .17). More eyes treated with topical medication first (82 [31%] of 261 eyes) than eyes treated with laser trabeculoplasty first (61 [23%] of 261 eyes) had confirmed localized deterioration at least once during follow-up (P = .02). Improvement was nearly twice as common as deterioration on masked subjective impression in both groups through 30 months (2 1/2 years). Eyes treated with laser trabeculoplasty first were judged to have slightly more improvement and slightly less deterioration than eyes treated with topical medication first. CONCLUSION: During follow-up, measures of visual field status for eyes treated with laser trabeculoplasty first were slightly better than those for eyes treated with topical medication first. Statistical significance was attained for only some of the differences, and the clinical implications of such small differences are not known.

Adult↗
PubMed2001

Otago glaucoma surgery outcome study : long-term results of uveitis with secondary glaucoma drained by Molteno implants.

OBJECTIVE: This study was undertaken in Otago, New Zealand, to provide data on the long-term results of cases of uveitis with secondary glaucoma drained by Molteno implants. DESIGN: A prospective, noncomparative case series of all cases of chronic uveitis with secondary glaucoma drained by Molteno implants from 1978 through 1998. PARTICIPANTS: Forty eyes of 35 patients. INTERVENTION: Insertion of Molteno implant. MAIN OUTCOME MEASURES: Intraocular pressure, visual acuity, and progressive visual field loss. RESULTS: Insertion of a Molteno implant was effective in controlling the intraocular pressure at 21 mmHg or less with a probability of 0.87 (95% confidence interval [CI], 0.76, 0.98) and 0.77 (95% CI, 0.60, 0.93) at 5 and 10 or more years after surgery. The mean visual acuity improved from 20/100 to 20/70 immediately after operation. This value declined to 20/130 at 5 and 10 years after surgery and then improved slightly to 20/120 at 15 years after surgery. In these eyes, the Kaplan-Meier estimated probability of retaining useful vision (visual acuity >20/400; visual field >5 degrees radius) was 0.75 (95% CI, 0.61, 0.89) and 0.71 (95% CI, 0.55, 0.87) at 5 and 7 or more years after surgery. CONCLUSIONS: The insertion of a Molteno implant controlled the intraocular pressure in 76% of cases over the follow-up period. Patients in whom the uveitis was well controlled maintained their visual acuity and visual fields, whereas the proportion of cases requiring steroids and the doses required fell progressively over the period of follow-up. Failures were related to complications of advanced disease, previous intraocular surgery, and failure to control the uveitis. The drainage system provided by the Molteno implant proved robust, continuing to function well despite continuous activity of the uveitis, acute exacerbations of the uveitis, and all subsequent intraocular surgery including cataract extraction, keratoplasty, and vitrectomy.

Adolescent↗
PubMed2001

Otago glaucoma surgery outcome study: long-term follow-up of cases of primary glaucoma with additional risk factors drained by Molteno implants.

OBJECTIVE: This study was undertaken to provide data on the long-term results of cases of primary open-angle glaucoma with additional risk factors drained by Molteno implants in the province of Otago, New Zealand. DESIGN: Prospective, noncomparative case series PARTICIPANTS: One hundred thirty eyes of 103 patients drained by Molteno implants as the first surgery between 1984 and 1999. INTERVENTION: Insertion of Molteno implant (Ethicon Inc., Johnson & Johnson, Somerville, NJ) using the Vicryl-tie technique. MAIN OUTCOME MEASURES: Intraocular pressure (IOP), visual acuity, visual field. RESULTS: Insertion of a Molteno implant controlled the IOP at 21 mmHg or less with a probability of 1.0 (95% confidence interval [CI], 0.90, 1.0) at up to 7 or more years after surgery. The mean preoperative visual acuity of 20/160 improved to 20/50 after operation and then declined to 20/55 at 5 years and 20/80 after 10 years. The probability of retaining useful vision (visual acuity, >20/400; visual field, >5 degrees radius) was 0.86 (95% CI, 0.77, 0.94) and 0.78 (95% CI, 0.67, 0.89) at 5 and 7 or more years, respectively, after surgery. CONCLUSIONS: The insertion of Molteno implants using the Vicryl-tie technique in this series of 130 cases of primary open-angle glaucoma with additional risk factors controlled the IOP in all cases.

Aged↗
PubMed1985

Complications of surgery in glaucoma. Suprachoroidal expulsive hemorrhage in glaucoma patients undergoing intraocular surgery.

A retrospective study of suprachoroidal expulsive hemorrhage in 1638 consecutive cases of intraocular surgery in patients with glaucoma identified 12 cases. A brief summary of each is presented. The pathogenesis of suprachoroidal expulsive hemorrhage is discussed, emphasizing the increased risk of this surgical complication in patients with glaucoma.

Adolescent↗
PubMed1992

Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group.

BACKGROUND: In a collaborative study, patients with untreated normal-tension glaucoma were randomly assigned to a marked intraocular pressure reduction group or to a no therapy group. It was anticipated that medical therapy and laser trabeculoplasty would generally not achieve adequate pressure lowering and that fistulizing surgery would be required. This hypothesis was examined using current observations in the study. METHODS: Patients randomized to the therapy group had a pressure reduction of at least 30% from their last prerandomization level. This was achieved within 6 months by means of fistulizing surgery or with pilocarpine and/or laser trabeculoplasty. Beta-blockers and adrenergic agonists were excluded from both eyes. RESULTS: Of 30 patients with documented stable 30% pressure reduction, 17 (57%) achieved this with topical medication and/or laser trabeculoplasty: 8 with pilocarpine alone, 2 with laser trabeculoplasty alone, and 7 with laser trabeculoplasty after initial topical medication. The remaining 13 (43%) patients required a single fistulizing procedure. There was no statistically significant difference between the mean follow-up time for the nonfistulized group (533.8 +/- 437.6 days) and for the fistulized group (502.7 +/- 344.7 days). Both treatment groups had similar baseline profiles. CONCLUSION: Marked pressure reduction can be achieved and maintained on a long-term basis by means other than fistulizing surgery in a large proportion of patients with untreated normal-tension glaucoma.

Aged↗
PubMed1988

[Parapapillary retinal vessel caliber. II. Caliber reduction in eyes with glaucoma (a papillometric study of 309 eyes with chronic simple glaucoma compared with 264 normal eyes)].

The diameter of the temporal superior or inferior artery and vein was measured at the optic disk border and 2 mm from the disk center in 309 nonselected eyes with chronic primary open-angle glaucoma. The values obtained were compared with those of 264 nonselected normal eyes. The calibers of both vessels were significantly larger in the normal eyes than in the glaucomatous ones (p = 0.000 or p less than 0.01; Wilcoxon-Mann-Whitney test). Their diameters diminished significantly (p less than 0.001) with decreasing width and area of the neuroretinal rim as a whole and when divided into different optic disk sectors, and with increasing optic cup area, horizontal and vertical cup/disk ratios, area of the subtotal to total parapapillary choriopigmentepithelioretinal atrophy, perimetric loss, and glaucoma stage. Thus, the caliber of the parapapillary retinal vessels decreases significantly with increasing glaucomatous optic nerve damage.

Adolescent↗
PubMed2001

Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.

We investigated the intraocular pressure (IOP)-lowering potential of latanoprost in patients with normal-tension glaucoma (NTG) or primary open-angle glaucoma (POAG). This prospective study included 59 NTG and 20 POAG patients treated with the following four dosing regimens of latanoprost: patients on no previous medication received latanoprost as initial therapy (Group 1, n=31), patients on beta-blocker therapy received latanoprost as adjunctive therapy (Group II, n=9), patients on unoprostone monotherapy were switched to latanoprost monotherapy (Group III, n=14), and patients previously on dual therapy with isopropyl unoprostone and beta-blocker were switched to a combined treatment of latanoprost and beta-blocker (Group IV, n=25). IOP significantly decreased 8 weeks after initiation of latanoprost therapy by 19.9% in Group I, 20.5% in Group II, 16.6% in Group III, and 12.2% in Group IV. In Groups I and II, there was a significant positive correlation between the magnitude of IOP reduction induced by latanoprost and the IOP level before latanoprost therapy. The IOP level before latanoprost therapy is a contributing factor in the IOP-lowering efficacy of latanoprost. Latanoprost is more effective in lowering IOP than isopropyl unoprostone.

Adrenergic beta-Antagonists↗
PubMed2000

The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.

The purpose of this study was to determine the effectiveness and safety of brimonidine 0.2% (Alphagan, Allergan Inc., Irvine, CA) as mono-, combination, or replacement therapy for reducing intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. The study method was an open-label, comparative clinical evaluation involving 2335 patients. During the 2-month trial, data were collected at baseline (visit 1), month 1 (visit 2), and month 2 (visit 3). Various parameters were evaluated, including glaucoma medications (visit 1), IOP (visit 1-visit 3), and adverse events. A subset cohort of 1254 patients was selected that met specific study criteria. Data from these 1254 patients were used to evaluate adverse events and the change in IOP from visit 1 to visit 3. Patient data were grouped according to specific drug regimen, and drug regimens were categorized into supergroups of mono-, combination, and replacement therapy. The results of the study revealed that the overall mean change in IOP for 1) monotherapy (n = 240) was -5.07 mm Hg (-20.2%), 2) combination therapy (n = 554) was -4.01 mm Hg (-16.9%), 3) replacement therapy (n = 460) was -2.33 mm Hg (-9.8%), and 4) overall (n = 1254) was -3.59 mm Hg (-14.9%) (p < 0.001 for all changes). Overall, 6.0% of the subjects reported adverse events, with no hypersensitivity or unexpected systemic or ocular adverse events. Eighty-five percent (85%) of clinicians rated brimonidine as "good" to "excellent". In conclusion, brimonidine is safe and effectively lowers IOP when used as mono-, combination, or replacement therapy as observed in a large community population.

Adrenergic alpha-Agonists↗
PubMed2006

Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma.

PURPOSE: To introduce a new method, derived from the Glaucoma Staging System (GSS), for classifying glaucomatous visual field defects. PATIENTS AND METHODS: Four sample groups composed respectively of 471 (sample #1), 128 (sample #2), 185 (sample #3), and 131 (sample #4) patients with either ocular hypertension or chronic glaucoma were considered. The GSS 2 uses both the MD and CPSD/CLV or PSD/LV perimetric indices to classify visual field defect in 6 stages and in 3 types (generalized, localized, and mixed). The formulas were determined using sample #1. A new borderline stage was created, on the basis of sample #2. The relationship between the PSD/LV and CPSD/CLV values was studied on sample #3 to verify the possibility of using the uncorrected indices instead of the CPSD/CLV. The relationship with other classification methods was studied on sample #4. RESULTS: The GSS 2 showed a strong level of association with the AGIS and the Hodapp-Parrish-Anderson methods in staging defect severity. A good correlation was also found with a classification based on the Bebie curve. CONCLUSIONS: The GSS 2 was able to correctly classify both damage severity and perimetric defect type in the sample studied, using either the corrected or uncorrected visual field indices. It is a quick and easy method, and its formulas can be introduced in any software.

Adult↗
PubMed2004

Comparison of survival of exfoliative glaucoma patients and primary open-angle glaucoma patients: impact of acetazolamide use.

PURPOSE: To compare the survival rates of patients with exfoliative glaucoma (XFG) and those with primary open-angle glaucoma (POAG), and to establish whether the use of acetazolamide has any influence on survival. METHODS: The survival data, including date and cause of death, for 1147 patients with XFG or POAG who were ultimately hospitalized at the Eye Department, National Hospital, Oslo, between 1961 and 1970, were analysed retrospectively. The Cox proportional hazard model was used in the survival analyses. RESULTS: No statistically significant differences in survival were found between patients with XFG and those with POAG (p = 0.85). As expected, female gender and younger age at diagnosis were associated with longer survival periods. Surprisingly, we found that patients with more recent birth dates had relatively lower survival rates than patients with earlier birth dates; when this was included in the analyses, the use of acetazolamide was found to be associated with reduced survival (n = 492, p = 0.02).

Acetazolamide↗
PubMed1975

The immediate response in applanation pressure to intravenous acetazolamide in primary glaucomas and glaucoma suspects.

The decays in the applanation pressures of both eyes, after a reduction of the aqueous secretion by means of intravenous acetazolamide, are studied with respect to shape and steepness by comparison with reference curves calculated from different values of the facility of aqueous outflow. The pressure decays in three out of four eyes with narrow-angle glaucoma exhibited "breaks" possibly resulting from a stepwise reopening of the chamber angle during the decompression. Twenty patients with intraocular hypertension and open angles could be divided into two groups according to the facility of aqueous outflow (in mul mmHg-1 min-1), estimated from approximately matching reference curves: Nine patients with facilities above 0.15 had normal visual fields and nearly indentical pressure curves of the two eyes. Out of 11 patients with facilities below 0.15, seven patients had glaucomatous visual field defects and excavated optic discs. The pressure curves of eye pairs in this low facility group showed asymmetry, and breaks were seen in approximately half of the curves. These might be caused by changes in the outflow facility due to a decompression of collapsed outflow channels. However, the morphological basis for such an interpretation is not as well founded as in the case of narrow-angle glaucoma.

Acetazolamide↗
PubMed1976

The cyclopentolate provocative test in suspected or untreated open-angle glaucoma. III. The significane of pigment for the result of the cyclopentolate provocative test in suspected or untreated open-angle glaucoma.

Significant elevations of IOP, i. e. responses, occurred in eyes with suspected or untreated open-angle glaucoma during the mydriasis test with 1% cyclopentolate (CPT). The possible role of pigment in the IOP elevations seen in the responders was studied. Pigment was liberated in the aqueous, sometimes very profusely, in 88 (31.9%) of 276 eyes during CPT. The maximal IOP elevations, ad 20 mmHg, were seen in just these eyes. They were eyes with capsular or pigmentary glaucoma or eyes in which exceptionally heavy pigment was demonstrated in the chamber angle for other reasons. There was a statistically significant correlation between pigment liberation and IOP elevation during CPT. Evidently profuse pigment liberation may have caused transient blocking of the trabecular meshwork, obstruction of aqueous outflow and elevation of IOP. Liberation of pigment in the aqueous during CPT was statistically highly significantly more profuse in eyes with pseudoexfoliation than in eyes without pseudoexfoliation. An equally significant correlation with demonstrated between the grade of chamber angle pigmentation and the degree of pigment liberation during CPT. The significance of pigment for IOP elevation was seen also in the statistically highly significantly more profuse pigmentation of the chamber angle in the responder than in the non-responder eyes.

Aqueous Humor↗
PubMed1991

Prevalence of migraine in low-tension glaucoma and primary open-angle glaucoma in Japanese.

We studied the prevalence of migraine in low-tension glaucoma (LTG) and primary open-angle glaucoma (POAG). Seventy seven Japanese patients with LTG, 73 with POAG, and 75 normal subjects were randomly selected and tested with a headache questionnaire. The prevalence of headache with or without typical migrainous features (unilateral headache or ocular pain, nausea, vomiting, and visual disturbance before headache) was 51% in LTG, 42% in POAG, and 44% in normal patients. The prevalence of headache with two migrainous features or more (probable migraine) was 17% in LTG, 11% in POAG, and 12% in normal subjects. The prevalence of headache with three migrainous features (classical migraine) was 5% in LTG, 3% in POAG, and 3% in normal subjects. There was no statistically significant difference in the prevalence of any types of migraine between the three groups of patients (p greater than 0.05). These results suggest there is no significant relationship between migraine and LTG or POAG in Japanese patients.

Adult↗